{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:14:18Z","timestamp":1794863658727,"version":"4.9.1"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017800","name":"UC San Diego Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017800","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cytogfr.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T15:15:42Z","timestamp":1746890142000},"page":"45-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["BCR-ABL: The molecular mastermind behind chronic myeloid leukemia"],"prefix":"10.1016","volume":"83","author":[{"given":"Tara","family":"Shammas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malalage N.","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April N.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-2175","authenticated-orcid":false,"given":"Daniel J.","family":"Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cytogfr.2025.05.001_bib1","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1172\/JCI31771","article-title":"Discovery of the Philadelphia chromosome: a personal perspective","volume":"117","author":"Nowell","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2025.05.001_bib2","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J. Natl. Cancer Inst."},{"issue":"5405","key":"10.1016\/j.cytogfr.2025.05.001_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"56","key":"10.1016\/j.cytogfr.2025.05.001_bib4","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1038\/sj.onc.1206080","article-title":"Philadelphia-positive leukemia: a personal perspective","volume":"21","author":"Heisterkamp","year":"2002","journal-title":"Oncogene"},{"issue":"5940","key":"10.1016\/j.cytogfr.2025.05.001_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.cytogfr.2025.05.001_bib7","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198512053132301","article-title":"Evidence of a new chimeric bcr\/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome","volume":"313","author":"Stam","year":"1985","journal-title":"N. Engl. J. Med"},{"issue":"5750","key":"10.1016\/j.cytogfr.2025.05.001_bib8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/283826a0","article-title":"Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine","volume":"283","author":"Witte","year":"1980","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib9","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.007","article-title":"Imatinib in chronic myeloid leukemia: an overview","volume":"6","author":"Sacha","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med"},{"issue":"14","key":"10.1016\/j.cytogfr.2025.05.001_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1525-1578(10)60454-0","article-title":"Clinical applications of BCR-ABL molecular testing in acute leukemia","volume":"5","author":"Nashed","year":"2003","journal-title":"J. Mol. Diagn."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.05.001_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S1525-1578(10)60532-6","article-title":"Measurement of relative copy number of CDKN2A\/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification","volume":"6","author":"Aveyard","year":"2004","journal-title":"J. Mol. Diagn."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood-2013-05-501312","article-title":"No familial aggregation in chronic myeloid leukemia","volume":"122","author":"Bjorkholm","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF01834384","article-title":"Chronic myelogenous leukemia and exposure to ionizing radiation--a retrospective study of 443 patients","volume":"70","author":"Corso","year":"1995","journal-title":"Ann. Hematol."},{"issue":"20","key":"10.1016\/j.cytogfr.2025.05.001_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205110","article-title":"Factors that affect the formation of chromosomal translocations in cells","volume":"14","author":"Canoy","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib18","article-title":"Re-evaluating the role of BCR\/ABL in chronic myelogenous leukemia","volume":"1","author":"Ross","year":"2014","journal-title":"Mol. Cell Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s004120050394","article-title":"The topological organization of chromosomes 9 and 22 in cell nuclei has a determinative role in the induction of t(9,22) translocations and in the pathogenesis of t(9,22) leukemias","volume":"108","author":"Kozubek","year":"1999","journal-title":"Chromosoma"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107325","article-title":"Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia","volume":"131","author":"Martinez-Castillo","year":"2023","journal-title":"Leuk. Res"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib21","unstructured":"G.M. da Silva, K. Lam, D.C. Dalgarno, C.M. Rubenstein, Compound mutations in the Abl1 kinase cause inhibitor resistance by shifting DFG flip mechanisms and relative state populations, arXiv arXiv:2405.14968, 2024.."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0092-8674(91)90148-R","article-title":"BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner","volume":"66","author":"Pendergast","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cytogfr.2022.08.003","article-title":"Nefarious NTRK oncogenic fusions in pediatric sarcomas: too many to Trk","volume":"68","author":"Aepala","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.05.001_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","article-title":"Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations","volume":"26","author":"Gallo","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.molmed.2016.11.002","article-title":"Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders","volume":"23","author":"Nelson","year":"2017","journal-title":"Trends Mol. Med"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib26","first-page":"218","article-title":"Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene","volume":"35","author":"Bellesso","year":"2013","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"44","key":"10.1016\/j.cytogfr.2025.05.001_bib27","doi-asserted-by":"crossref","first-page":"33577","DOI":"10.1074\/jbc.M605604200","article-title":"Structure and chemical inhibition of the RET tyrosine kinase domain","volume":"281","author":"Knowles","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"30","key":"10.1016\/j.cytogfr.2025.05.001_bib28","doi-asserted-by":"crossref","first-page":"28929","DOI":"10.18632\/oncotarget.4325","article-title":"Identification and characterization of RET fusions in advanced colorectal cancer","volume":"6","author":"Le Rolle","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3324\/haematol.2019.220871","article-title":"Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation","volume":"105","author":"Peiris","year":"2020","journal-title":"Haematologica"},{"issue":"28","key":"10.1016\/j.cytogfr.2025.05.001_bib30","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.18632\/oncotarget.26837","article-title":"BCR: a promiscuous fusion partner in hematopoietic disorders","volume":"10","author":"Peiris","year":"2019","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2013.088674","article-title":"NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins","volume":"99","author":"De Keersmaecker","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib32","first-page":"50","article-title":"An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL","volume":"6","author":"Kakadia","year":"2016","journal-title":"Leuk. Res Rep."},{"key":"10.1016\/j.cytogfr.2025.05.001_bib33","article-title":"RCSD1-ABL1 translocation associated with IKZF1 gene deletion in B-cell acute lymphoblastic leukemia","volume":"2015","author":"Kamran","year":"2015","journal-title":"Case Rep. Hematol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s13287-021-02659-1","article-title":"Chronic myeloid leukemia stem cells: targeting therapeutic implications","volume":"12","author":"Mojtahedi","year":"2021","journal-title":"Stem Cell Res Ther."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.05.001_bib35","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.cytogfr.2025.05.001_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213615","article-title":"An overview of myeloid blast-phase chronic myeloid leukemia","volume":"16","author":"Pamuk","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.05.001_bib37","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib38","series-title":"American Cancer Society Cancer Facts & Figures 2024","author":"ACS","year":"2024"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia","volume":"29","author":"Cortes","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib40","first-page":"607","article-title":"Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment","volume":"4","author":"Cowell","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000341289","article-title":"A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia\/lymphoma, successfully treated by cord blood transplantation","volume":"129","author":"Morishige","year":"2013","journal-title":"Acta Haematol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib42","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.05.001_bib43","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2017.07.006","article-title":"Epigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic options","volume":"51","author":"Koschmieder","year":"2018","journal-title":"Semin Cancer Biol."},{"issue":"18","key":"10.1016\/j.cytogfr.2025.05.001_bib45","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.05.001_bib46","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41375-024-02365-w","article-title":"BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): the new frontier in the treatment of Ph(+) leukemias?","volume":"38","author":"Cruz-Rodriguez","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.05.001_bib48","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.05.001_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104994","article-title":"Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML)","volume":"299","author":"Zhang","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2025.05.001_bib50","doi-asserted-by":"crossref","DOI":"10.3402\/fnr.v58.23364","article-title":"Health effects of protein intake in healthy elderly populations: a systematic literature review","volume":"58","author":"Pedersen","year":"2014","journal-title":"Food Nutr. Res"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib51","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-12-304","article-title":"Myeloid malignancies: mutations, models and management","volume":"12","author":"Murati","year":"2012","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.05.001_bib52","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3892\/mmr.2014.1951","article-title":"Incidence of bcrabl fusion transcripts in healthy individuals","volume":"9","author":"Ismail","year":"2014","journal-title":"Mol. Med Rep."},{"issue":"17","key":"10.1016\/j.cytogfr.2025.05.001_bib53","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.05.001_bib54","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J. Exp. Med"},{"issue":"16","key":"10.1016\/j.cytogfr.2025.05.001_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165776","article-title":"Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities","volume":"21","author":"Komorowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.05.001_bib56","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0145-2126(01)00197-7","article-title":"Bcr-Abl variants: biological and clinical aspects","volume":"26","author":"Advani","year":"2002","journal-title":"Leuk. Res"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib57","article-title":"Future approaches for treating chronic myeloid leukemia: CRISPR therapy","volume":"10","author":"Vuelta","year":"2021","journal-title":"Biol. (Basel)"},{"issue":"6325","key":"10.1016\/j.cytogfr.2025.05.001_bib58","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/351400a0","article-title":"Bcr encodes a GTPase-activating protein for p21rac","volume":"351","author":"Diekmann","year":"1991","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib59","first-page":"117","article-title":"Structure of the Bcr-Abl oncoprotein oligomerization domain","volume":"9","author":"Zhao","year":"2002","journal-title":"Nat. Struct. Biol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0092-8674(91)90521-Y","article-title":"The BCR gene encodes a novel serine\/threonine kinase activity within a single exon","volume":"67","author":"Maru","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib61","article-title":"The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modeling and virtual screening approach","volume":"9","author":"Huang","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib62","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.cytogfr.2025.05.001_bib63","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.onc.1210841","article-title":"The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation","volume":"27","author":"Sahay","year":"2008","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib64","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41467-017-02313-6","article-title":"Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase","volume":"8","author":"Reckel","year":"2017","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.cytogfr.2025.05.001_bib65","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1091\/mbc.e13-06-0333","article-title":"The Rac-GAP Bcr is a novel regulator of the Par complex that controls cell polarity","volume":"24","author":"Narayanan","year":"2013","journal-title":"Mol. Biol. Cell"},{"issue":"13","key":"10.1016\/j.cytogfr.2025.05.001_bib66","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1128\/MCB.23.13.4663-4672.2003","article-title":"The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain","volume":"23","author":"Radziwill","year":"2003","journal-title":"Mol. Cell Biol."},{"issue":"139","key":"10.1016\/j.cytogfr.2025.05.001_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: evolution of function, regulation, and specificity","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci. Signal."},{"issue":"56","key":"10.1016\/j.cytogfr.2025.05.001_bib68","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206094","article-title":"BCR\/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations","volume":"21","author":"Pane","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-018-0788-y","article-title":"Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products","volume":"17","author":"Siveen","year":"2018","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trecan.2015.07.004","article-title":"The emerging role of ABL kinases in solid tumors","volume":"1","author":"Wang","year":"2015","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib71","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/107327480901600202","article-title":"Signaling networks associated with BCR-ABL-dependent transformation","volume":"16","author":"Hazlehurst","year":"2009","journal-title":"Cancer Control"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.05.001_bib72","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1074\/jbc.R112.438382","article-title":"Structure and dynamic regulation of Abl kinases","volume":"288","author":"Panjarian","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1097-2765(03)00274-0","article-title":"Autoinhibition of Bcr-Abl through its SH3 domain","volume":"12","author":"Smith","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib74","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1038\/ncomms6470","article-title":"The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility","volume":"5","author":"Lamontanara","year":"2014","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib75","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/MCB.01454-13","article-title":"The capable ABL: what is its biological function?","volume":"34","author":"Wang","year":"2014","journal-title":"Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017020","article-title":"Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL","volume":"6","author":"Preyer","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib77","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/j.1460-2075.1996.tb00503.x","article-title":"The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products","volume":"15","author":"Wen","year":"1996","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/ncb1228","article-title":"JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage","volume":"7","author":"Yoshida","year":"2005","journal-title":"Nat. Cell Biol."},{"issue":"37","key":"10.1016\/j.cytogfr.2025.05.001_bib79","doi-asserted-by":"crossref","first-page":"22823","DOI":"10.1074\/jbc.271.37.22823","article-title":"Binding of A\/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase","volume":"271","author":"Miao","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.05.001_bib80","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/j.1460-2075.1993.tb05797.x","article-title":"An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias","volume":"12","author":"McWhirter","year":"1993","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.05.001_bib84","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.05.001_bib85","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1128\/MCB.15.10.5531","article-title":"Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis","volume":"15","author":"Cortez","year":"1995","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib86","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"65","key":"10.1016\/j.cytogfr.2025.05.001_bib87","doi-asserted-by":"crossref","first-page":"108880","DOI":"10.18632\/oncotarget.22353","article-title":"Matrine inhibits BCR\/ABL mediated ERK\/MAPK pathway in human leukemia cells","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"issue":"252","key":"10.1016\/j.cytogfr.2025.05.001_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med"},{"issue":"22","key":"10.1016\/j.cytogfr.2025.05.001_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212573","article-title":"Perturbation of p38alpha MAPK as a novel strategy to effectively sensitize chronic myeloid leukemia cells to therapeutic BCR-ABL inhibitors","volume":"22","author":"Kuo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.05.001_bib90","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-024-02282-y","article-title":"Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1","volume":"38","author":"Fontana","year":"2024","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.cytogfr.2025.05.001_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163949","article-title":"The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review","volume":"13","author":"Rascio","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib92","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood.V88.5.1542.1542","article-title":"PI 3-kinase activation in BCR\/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR\/abl","volume":"88","author":"Jain","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib93","first-page":"1107","article-title":"Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants","volume":"11","author":"Varticovski","year":"1991","journal-title":"Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib94","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/cgt.2014.65","article-title":"BCR\/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts","volume":"22","author":"Li","year":"2015","journal-title":"Cancer Gene Ther."},{"issue":"20","key":"10.1016\/j.cytogfr.2025.05.001_bib95","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"B. Calabretta, Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.05.001_bib96","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1158\/0008-5472.CAN-04-3888","article-title":"ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors","volume":"65","author":"Kharas","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib97","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/DDDT.S132092","article-title":"Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines","volume":"11","author":"Xin","year":"2017","journal-title":"Drug Des. Devel Ther."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib98","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jnci\/djx236","article-title":"Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition","volume":"110","author":"Mitchell","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib99","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12032-021-01462-5","article-title":"Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: a review","volume":"38","author":"Singh","year":"2021","journal-title":"Med Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2013.098442","article-title":"Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy","volume":"99","author":"Bibi","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"5404","key":"10.1016\/j.cytogfr.2025.05.001_bib102","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1126\/science.283.5404.990","article-title":"Erythropoietin receptor activation by a ligand-induced conformation change","volume":"283","author":"Remy","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib103","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1054-3589(08)60111-8","article-title":"Cytokines and STAT signaling","volume":"47","author":"Schindler","year":"2000","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.cytogfr.2025.05.001_bib104","doi-asserted-by":"crossref","first-page":"1075192","DOI":"10.3389\/fimmu.2022.1075192","article-title":"Molecular dissection of Janus kinases as drug targets for inflammatory diseases","volume":"13","author":"Kwon","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.05.001_bib105","first-page":"6675","article-title":"DNA binding specificity of different STAT proteins","volume":"276","author":"Ehret","year":"2001","journal-title":"Comp. Vitr. Specif. Nat. Target sites, J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib106","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib107","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J. Exp. Med"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib108","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V94.3.1108.415k07_1108_1112","article-title":"STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells","volume":"94","author":"de Groot","year":"1999","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.05.001_bib109","first-page":"1724","article-title":"BCR\/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats","volume":"10","author":"Frank","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.omto.2020.06.008","article-title":"A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL\/JAK-STAT Pathway","volume":"18","author":"Wei","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.05.001_bib111","doi-asserted-by":"crossref","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-kappaB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.05.001_bib112","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.4049\/jimmunol.173.9.5786","article-title":"A role for NF-kappa B subunits p50 and p65 in the inhibition of lipopolysaccharide-induced shock","volume":"173","author":"Gadjeva","year":"2004","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.05.001_bib113","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+\u2009cells sensitive and resistant to STI571","volume":"102","author":"Yu","year":"2003","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.cytogfr.2025.05.001_bib114","doi-asserted-by":"crossref","first-page":"66287","DOI":"10.18632\/oncotarget.11507","article-title":"The BCR-ABL\/NF-kappaB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias","volume":"7","author":"Carra","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib115","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","article-title":"Jr., A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation","volume":"12","author":"Reuther","year":"1998","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib116","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13046-022-02298-1","article-title":"FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-kappaB signaling activation","volume":"41","author":"Yang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib117","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","author":"Iqbal","year":"2014","journal-title":"Chemother. Res Pr. 2014"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.05.001_bib118","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.7150\/jca.38752","article-title":"BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia","volume":"11","author":"Cai","year":"2020","journal-title":"J. Cancer"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.05.001_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.45","article-title":"Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"1","author":"da Rocha","year":"2011","journal-title":"Blood Cancer J."},{"issue":"20","key":"10.1016\/j.cytogfr.2025.05.001_bib120","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib121","first-page":"281","article-title":"Dasatinib in chronic myeloid leukemia: a review","volume":"5","author":"Aguilera","year":"2009","journal-title":"Ther. Clin. Risk Manag"},{"issue":"23","key":"10.1016\/j.cytogfr.2025.05.001_bib122","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res"},{"issue":"5682","key":"10.1016\/j.cytogfr.2025.05.001_bib123","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.05.001_bib124","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.05.001_bib125","first-page":"451","article-title":"Bosutinib: a novel src\/abl kinase inhibitor for chronic myelogenous leukemia","volume":"4","author":"Steinbach","year":"2013","journal-title":"J. Adv. Pr. Oncol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.05.001_bib126","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/leu.2015.42","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.05.001_bib127","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/ajh.26686","article-title":"Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia","volume":"97","author":"Kantarjian","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.05.001_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078556","article-title":"Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study","volume":"8","author":"Tanneeru","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib129","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"Onco Targets Ther."},{"issue":"21","key":"10.1016\/j.cytogfr.2025.05.001_bib130","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103580","article-title":"Development of asciminib, a novel allosteric inhibitor of BCR-ABL1","volume":"171","author":"Rea","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib132","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib133","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cytogfr.2025.05.001_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29174280","article-title":"Promising therapeutic strategies for hematologic malignancies: innovations and potential","volume":"29","author":"Lica","year":"2024","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib135","article-title":"New targets for CAR T therapy in hematologic malignancies","volume":"34","author":"Savani","year":"2021","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib136","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/blood-2016-12-757336","article-title":"Fall of the mutants: T cells targeting BCR-ABL","volume":"129","author":"Lulla","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.942053","article-title":"JAK2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies","volume":"10","author":"Downes","year":"2022","journal-title":"Front Cell Dev. Biol."},{"issue":"20","key":"10.1016\/j.cytogfr.2025.05.001_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15204957","article-title":"Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers","volume":"15","author":"Xu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib139","article-title":"The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia","volume":"254","author":"El-Tanani","year":"2024","journal-title":"Pathol. Res Pr."},{"issue":"17","key":"10.1016\/j.cytogfr.2025.05.001_bib140","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/bloodadvances.2020004174","article-title":"Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance","volume":"5","author":"Chen","year":"2021","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib141","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.cytogfr.2025.05.001_bib142","doi-asserted-by":"crossref","first-page":"659","DOI":"10.18632\/oncotarget.28228","article-title":"Proteomic analysis reveals dual requirement for Grb2 and PLCgamma1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation","volume":"13","author":"Peiris","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108344","article-title":"O.S. H, J. Wu, S.A. Mani, V. Subbiah, RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives","volume":"242","author":"Addeo","year":"2023","journal-title":"Pharm. Ther."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.05.001_bib144","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/leu.2012.109","article-title":"RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation","volume":"26","author":"Ballerini","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.05.001_bib145","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.18632\/oncotarget.24020","article-title":"mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL","volume":"9","author":"Gotesman","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.05.001_bib146","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/MPH.0000000000001249","article-title":"Cryptic ETV6-ABL1 Fusion and MLL2 Truncation Revealed by Integrative Clinical Sequencing in Multiply Relapsed Acute Lymphoblastic Leukemia","volume":"41","author":"Mankuzhy","year":"2019","journal-title":"J. Pediatr. Hematol. \/Oncol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.05.001_bib147","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/oncolo\/oyab052","article-title":"Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy","volume":"27","author":"Nardi","year":"2022","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib148","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","article-title":"Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics","volume":"31","author":"Reckel","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib149","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40164-022-00265-2","article-title":"Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era","volume":"11","author":"Shi","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib150","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-020-01082-4","article-title":"Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets","volume":"35","author":"Adnan-Awad","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2025.05.001_bib151","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.05.001_bib152","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.3324\/haematol.2018.192534","article-title":"A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210(BCR-ABL1) and P195(BCR-ABL1) isoforms","volume":"103","author":"Vinhas","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.05.001_bib153","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood.V95.9.2913.009k32_2913_2921","article-title":"Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases","volume":"95","author":"Quackenbush","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.05.001_bib154","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2284038","article-title":"A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes","volume":"28","author":"Zenebe","year":"2023","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.05.001_bib155","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1046\/j.1365-2141.1998.01098.x","article-title":"P230 BCR\/ABL protein may be associated with an acute leukaemia phenotype","volume":"103","author":"Haskovec","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.05.001_bib156","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/leu.2010.174","article-title":"Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation","volume":"24","author":"Score","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.05.001_bib157","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.05.001_bib158","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1214","article-title":"Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance","volume":"12","author":"Okamoto","year":"2024","journal-title":"Pharm. Res Perspect."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.05.001_bib159","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T04:47:43Z","timestamp":1749358063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":159,"alternative-id":["S1359610125000474"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.05.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCR-ABL: The molecular mastermind behind chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}